Table 1.

Baseline patient demographics and clinical characteristics.

Number of patients (men/women)
CD	30 (14/16)
UC	22 (15/7)
	Men	Women
Age before therapy, median (range)	37 (19.0–71.0)	39 (18.0–61.0)
Age at diagnosis, median (range)	30 (14.0–58.0)	28.5 (13.0–55.0)
Disease activity, median (range)
Mayo score	4 (0.0–10.0)	8 (0.0–9.0)
CDAI	186 (0.0–345.0)	283 (0.0–400.0)
CRP, median (range)	28 (0.0–85.0)	11 (0.0–57.0)
Weight, median (range)	80 (55.0–168.0)	63 (45.0–97.0)
Site of disease in CD, n (%)	All patients
Small intestine	23 (76.7)
Colon	22 (73.3)
Perianal fistula	9 (30.0)
Other types of fistula	2 (6.7)
Previous treatment, n (%)
5-aminosalicylates	47 (90.4)
Oral corticosteroids	46 (88.5)
Azathioprine	39 (75.0)
Others	10 (19.2)
Concomitant treatment, n (%)
5-aminosalicylates	40 (76.9)
Oral corticosteroids (low dose)	14 (26.9)
Azathioprine	29 (55.8)
Others	4 (7.7)

CD: Crohn’s disease; CDAI: Crohn’s Disease Activity Index; CRP: C-reactive protein; UC: ulcerative colitis.